Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Cardiovascular Imaging Reports
Erschienen in: Current Cardiovascular Imaging Reports 2/2011

01.04.2011

Measuring Treatment Effects in Clinical Trials Using Cardiac MRI

verfasst von: Suzanne de Waha, Georg Fuernau, Ingo Eitel, Philipp Lurz, Steffen Desch, Gerhard Schuler, Holger Thiele

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Cardiac MRI (CMR) offers the potential to assess valid and reliable parameters associated with cardiac diseases and the corresponding clinical prognosis. It has therefore emerged as a tool for outcome measures, resulting in lower study sample sizes, shorter duration of clinical studies, and subsequently less trial costs. This review focuses on the theoretical and practical background of CMR in measuring treatment effects in clinical trials.
Literatur
1.
•• Ward MM: Primer: measuring the effects of treatment in clinical trials. Nat Clin Pract Rheumatol 2007, 3:291-7. This paper focuses on the basic features of clinical trials and their impact on the interpretation of the results. PubMedCrossRef
2.
• Pennell DJ: Cardiovascular magnetic resonance. Circulation 2010, 121:692-705. This review reports on current clinical indications of CMR throughout a broad range of clinical applications. PubMedCrossRef
3.
• Coelho-Filho OR, Nallamshetty L, Kwong RY: Risk stratification for therapeutic management and prognosis. Heart Fail Clin 2009, 5:437-55, vii. This article reviews the current evidence on the prognostic impact of CMR in a wide range of cardiac conditions. PubMedCrossRef
4.
Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95
5.
Committee for Proprietary Medicinal Products (CPMP). Statistical Priniciples for Clinical Trials (ICH Topic E9). CPMP/ICH/363/96. In London, UK 1998.
6.
Browner W: Getting ready to estimate sample size: hypotheses and underlying principles. In Designing clinical research: an epidemiologic approach, edn 2, 51-64 (Eds Hulley SB et al) 2001
7.
Chow SC LJ: Design and analysis of clinical trials. New York: John Wiley and Sons 1998
8.
Lockie T, Nagel E, Redwood S, Plein S: Use of cardiovascular magnetic resonance imaging in acute coronary syndromes. Circulation 2009, 119:1671-81.PubMedCrossRef
9.
Bellenger NG, Burgess MI, Ray SG, et al.: Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 2000, 21:1387-96.PubMedCrossRef
10.
Stewart S, MacIntyre K, Hole DJ, et al.: More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001, 3:315-22.PubMedCrossRef
11.
Dill T, Schachinger V, Rolf A, et al.: Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 2009, 157:541-7.PubMedCrossRef
12.
Thiele H, Schuster A, Erbs S, et al.: Cardiac magnetic resonance imaging at 3 and 15 months after application of circulating progenitor cells in recanalised chronic total occlusions. Int J Cardiol 2009, 135:287-95.PubMedCrossRef
13.
Yusuf S, Diener HC, Sacco RL, et al.: Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225-37.PubMedCrossRef
14.
Cowan BR, Young AA, Anderson C, et al.: Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global End point Trial [ONTARGET]). Am J Cardiol 2009, 104:1484-9.PubMedCrossRef
15.
Shimada YJ, Shiota M, Siegel RJ, Shiota T: Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J Am Soc Echocardiogr 2010, 23:943-53.PubMedCrossRef
16.
Kim HK, Kim YJ, Park EA, et al.: Assessment of haemodynamic effects of surgical correction for severe functional tricuspid regurgitation: cardiac magnetic resonance imaging study. Eur Heart J 2010, 31:1520-8.PubMedCrossRef
17.
Jahnke C, Fischer J, Gerds-Li JH, et al.: Serial monitoring of reverse left-atrial remodeling after pulmonary vein isolation in patients with atrial fibrillation: A magnetic resonance imaging study. Int J Cardiol 2010.
18.
Nagel E, Lehmkuhl HB, Bocksch W, et al.: Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation 1999, 99:763-70.PubMed
19.
Schwitter J, Wacker CM, van Rossum AC, et al.: MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J 2008, 29:480-9.PubMedCrossRef
20.
Watkins S, McGeoch R, Lyne J, et al.: Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation 2009, 120:2207-13.PubMedCrossRef
21.
Ingkanisorn WP, Kwong RY, Bohme NS, et al.: Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol 2006, 47:1427-32.PubMedCrossRef
22.
Jahnke C, Nagel E, Gebker R, et al.: Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation 2007, 115:1769-76.PubMedCrossRef
23.
Chan CW, Kwong YL, Kwong RY, et al.: Improvement of myocardial perfusion reserve detected by cardiovascular magnetic resonance after direct endomyocardial implantation of autologous bone marrow cells in patients with severe coronary artery disease. J Cardiovasc Magn Reson 2010, 12:6.PubMedCrossRef
24.
Kwong RY, Chan AK, Brown KA, et al.: Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006, 113:2733-43.PubMedCrossRef
25.
Plein S, Younger JF, Sparrow P, et al.: Cardiovascular magnetic resonance of scar and ischemia burden early after acute ST elevation and non-ST elevation myocardial infarction. J Cardiovasc Magn Reson 2008, 10:47.PubMedCrossRef
26.
Kim RJ, Albert TS, Wible JH, et al.: Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 2008, 117:629-37.PubMedCrossRef
27.
Wagner A, Mahrholdt H, Holly TA, et al.: Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003, 361:374-9.PubMedCrossRef
28.
Kelle S, Roes SD, Klein C, et al.: Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 2009, 54:1770-7.PubMedCrossRef
29.
Thiele H, Schindler K, Friedenberger J, et al.: Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008, 118:49-57.PubMedCrossRef
30.
Atar D, Petzelbauer P, Schwitter J, et al.: Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009, 53:720-9.PubMedCrossRef
31.
de Waha S, Desch S, Eitel I, et al.: Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. Eur Heart J 2010.
32.
Sardella G, Mancone M, Bucciarelli-Ducci C, et al.: Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol 2009, 53:309-15.PubMedCrossRef
33.
Aletras AH, Tilak GS, Natanzon A, et al.: Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation 2006, 113:1865-70.PubMedCrossRef
34.
Friedrich MG, Abdel-Aty H, Taylor A, et al.: The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1581-7.PubMedCrossRef
35.
Eitel I, Desch S, Fuernau G, et al.: Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010, 55:2470-9.PubMedCrossRef
36.
Lonborg J, Kelbaek H, Vejlstrup N, et al.: Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv 2010, 3:34-41.PubMedCrossRef
37.
Thiele H, Hildebrand L, Schirdewahn C, et al.: Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 2010, 55:2201-9.PubMedCrossRef
38.
Ganame J, Messalli G, Dymarkowski S, et al.: Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J 2009, 30:1440-9.PubMedCrossRef
39.
Lamb HJ, Beyerbacht HP, de Roos A, et al.: Left ventricular remodeling early after aortic valve replacement: differential effects on diastolic function in aortic valve stenosis and aortic regurgitation. J Am Coll Cardiol 2002, 40:2182-8.PubMedCrossRef
40.
Oosterhof T, van Straten A, Vliegen HW, et al.: Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. Circulation 2007, 116:545-51.PubMedCrossRef
41.
Lurz P, Nordmeyer J, Muthurangu V, et al.: Comparison of bare metal stenting and percutaneous pulmonary valve implantation for treatment of right ventricular outflow tract obstruction: use of an x-ray/magnetic resonance hybrid laboratory for acute physiological assessment. Circulation 2009, 119:2995-3001.PubMedCrossRef
42.
Kirk P, Roughton M, Porter JB, et al.: Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009, 120:1961-8.PubMedCrossRef
43.
Modell B, Khan M, Darlison M, et al.: Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008, 10:42.PubMedCrossRef
44.
Assomull RG, Prasad SK, Lyne J, et al.: Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006, 48:1977-85.PubMedCrossRef
45.
Bruder O, Wagner A, Jensen CJ, et al.: Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:875-87.PubMedCrossRef
46.
Hughes DA, Elliott PM, Shah J, et al.: Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008, 94:153-8.PubMedCrossRef
47.
Vignaux O, Dhote R, Duboc D, et al.: Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 2002, 122:1895-901.PubMedCrossRef
48.
Friedrich MG, Sechtem U, Schulz-Menger J, et al.: Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009, 53:1475-87.PubMedCrossRef
49.
Butler CR, Thompson R, Haykowsky M, et al.: Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J Cardiovasc Magn Reson 2009, 11:7.PubMedCrossRef
50.
Gaddam K, Corros C, Pimenta E, et al.: Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010, 55:1137-42.PubMedCrossRef
51.
Kirschbaum SW, Springeling T, Boersma E, et al.: Complete percutaneous revascularization for multivessel disease in patients with impaired left ventricular function: pre- and post-procedural evaluation by cardiac magnetic resonance imaging. JACC Cardiovasc Interv 2010, 3:392-400.PubMedCrossRef
52.
Pegg TJ, Selvanayagam JB, Francis JM, et al.: A randomized trial of on-pump beating heart and conventional cardioplegic arrest in coronary artery bypass surgery patients with impaired left ventricular function using cardiac magnetic resonance imaging and biochemical markers. Circulation 2008, 118:2130-8.PubMedCrossRef
53.
Yao K, Huang R, Qian J, et al.: Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function. Heart 2008, 94:1147-53.PubMedCrossRef
54.
Pegg TJ, Selvanayagam JB, Karamitsos TD, et al.: Effects of off-pump versus on-pump coronary artery bypass grafting on early and late right ventricular function. Circulation 2008, 117:2202-10.PubMedCrossRef
55.
Webb CM, Elkington AG, Kraidly MM, et al.: Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 2008, 101:618-24.PubMedCrossRef
56.
Cheng AS, Selvanayagam JB, Jerosch-Herold M, et al.: Percutaneous treatment of chronic total coronary occlusions improves regional hyperemic myocardial blood flow and contractility: insights from quantitative cardiovascular magnetic resonance imaging. JACC Cardiovasc Interv 2008, 1:44-53.PubMedCrossRef
57.
Abbate A, Kontos MC, Grizzard JD, et al.: Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010, 105:1371-7 e1PubMedCrossRef
58.
Wohrle J, Merkle N, Mailander V, et al.: Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol 2010, 105:804-12.PubMedCrossRef
59.
Haeck JD, Kuijt WJ, Koch KT, et al.: Infarct size and left ventricular function in the PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-segment Elevation (PREPARE) trial: ancillary cardiovascular magnetic resonance study. Heart 2010, 96:190-5.PubMedCrossRef
60.
Patel MR, Worthley SG, Stebbins A, et al.: Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. JACC Cardiovasc Imaging 2010, 3:52-60.PubMedCrossRef
61.
Weir RA, Mark PB, Petrie CJ, et al.: Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 2009, 157:1088-96.PubMedCrossRef
62.
Tendera M, Wojakowski W, Ruzyllo W, et al.: Intracoronary infusion of bone marrow-derived selected CD34 + CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009, 30:1313-21.PubMedCrossRef
63.
Song YB, Hahn JY, Gwon HC, et al.: Upstream high-dose tirofiban does not reduce myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging pilot study. Clin Cardiol 2009, 32:321-6.PubMedCrossRef
64.
Hahn JY, Gwon HC, Choe YH, et al.: Effects of balloon-based distal protection during primary percutaneous coronary intervention on early and late infarct size and left ventricular remodeling: a pilot study using serial contrast-enhanced magnetic resonance imaging. Am Heart J 2007, 153:665 e1-8.
65.
Engelmann MG, Theiss HD, Hennig-Theiss C, et al.: Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006, 48:1712-21.PubMedCrossRef
66.
Kang HJ, Lee HY, Na SH, et al.: Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation 2006, 114:I145-51.PubMed
67.
Ripa RS, Jorgensen E, Wang Y, et al.: Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006, 113:1983-92.PubMedCrossRef
68.
Janssens S, Dubois C, Bogaert J, et al.: Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006, 367:113-21.PubMedCrossRef
69.
Thiele H, Engelmann L, Elsner K, et al.: Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005, 26:1956-63.PubMedCrossRef
70.
Gick M, Jander N, Bestehorn HP, et al.: Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 2005, 112:1462-9.PubMedCrossRef
71.
Wollert KC, Meyer GP, Lotz J, et al.: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141-8.PubMedCrossRef
72.
Gelfand EV, Haffajee JA, Hauser TH, et al.: Predictors of preserved left ventricular systolic function after surgery for chronic organic mitral regurgitation: a prospective study. J Heart Valve Dis 2010, 19:43-50.PubMed
73.
Tanner MA, Galanello R, Dessi C, et al.: Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008, 10:12.PubMedCrossRef
74.
Shimada T, Shimada K, Sakane T, et al.: Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001, 110:520-7.PubMedCrossRef
Metadaten
Titel
Measuring Treatment Effects in Clinical Trials Using Cardiac MRI
verfasst von
Suzanne de Waha
Georg Fuernau
Ingo Eitel
Philipp Lurz
Steffen Desch
Gerhard Schuler
Holger Thiele
Publikationsdatum
01.04.2011
Verlag
Current Science Inc.
Erschienen in
Current Cardiovascular Imaging Reports / Ausgabe 2/2011
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-011-9069-5

Weitere Artikel der Ausgabe 2/2011

Current Cardiovascular Imaging Reports 2/2011 Zur Ausgabe

ReviewPaper

Modeling and Registration for Electrophysiology Procedures Based on Three-Dimensional Imaging

ReviewPaper

Cardiovascular Applications of Hyperpolarized MRI

Clinical Trial Report

Does Late Enhancement Imaging Decipher the Role of Myocardial Fibrosis in Hypertrophic Cardiomyopathy?

ReviewPaper

Imaging as an End Point in Ischemia Trials

ReviewPaper

MR and CT: When to Use Each

ReviewPaper

Coronary MRA: Technical Advances and Clinical Applications

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen